Results 111 to 120 of about 24,588 (279)

The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma [PDF]

, 2002
Roland Buhl, G. Hanf, M. Solèr, George Bensch, Jeremy D. Wolfe, F Everhard, Kate Champain, H. Fox, J. Thirlwell   +8 more
openalex   +1 more source

[Clinical efficacy of omalizumab for treatment of moderate or severe allergic asthma in children with serum immunoglobulin E levels >1 500 IU/mL: a prospective study]. [PDF]

, 2023
Ming-Xin Luo, Hua Shan, Wen Wei
openalex   +1 more source

Simulating the impact of an educational and digital approach using patient journey modelling to overcome practical challenges in the management of chronic spontaneous urticaria in Germany

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objective Despite the availability of guidelines and effective escalation therapies, chronic spontaneous urticaria (CSU) is often inadequately treated in Germany. Implementation science can help to transfer evidence‐based care into practice.
Ralph von Kiedrowski, Mark Berneburg, Mona Biermann, Hanna Bonnekoh, Michael Fritz, Max Tischler, Martin Metz, Sebastian Volc, Nicola Wagner, Alexander Zink, Petra Nathan   +10 more
wiley   +1 more source

Effective treatment of a child with adenoidal hypertrophy and severe asthma by omalizumab: a case report [PDF]

, 2022
Haijing Sui, Huishan Zhang, Wei Ding, Zuotao Zhao, Jiali Mo, Jiajing Yuan, Leping Ye   +6 more
openalex   +1 more source

Adjuvant therapy of severe and/or refractory bullous pemphigoid with immunoadsorption – A prospective monocenter pilot study

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Bullous pemphigoid (BP) is the most common autoimmune blistering disease in the Western world. While remission is achieved in the majority of BP patients by long‐term use of corticosteroids with or without immunomodulants/immunosuppressants, national and international guidelines recommend adjuvant immunoadsorption (IA)
Maike M. Holtsche, Nina van Beek, Christoph M. Hammers, Artem Vorobyev, Michael Kasperkiewicz, Nina Schumacher, Philip Muck, Enno Schmidt   +7 more
wiley   +1 more source

Omalizumab is Effective and Safe in the Treatment of Japanese Cedar Pollen-induced Seasonal Allergic Rhinitis

Allergology International, 2006
Background: Seasonal allergic rhinitis (SAR) induced by Japanese cedar pollen is a substantial problem in Japan. Omalizumab, a novel humanized monoclonal anti-immunoglobulin E (IgE) antibody, has already been proven to reduce symptoms associated with SAR.
Kimihiro Okubo, Satoshi Ogino, Toshikazu Nagakura, Takeru Ishikawa   +3 more
doaj   +1 more source

Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria [PDF]

, 2015
Allen P. Kaplan, Marta Ferrer, Jonathan A. Bernstein, Evgeniya Antonova, Benjamin Trzaskoma, Karina Raimundo, Karin Rosén, Theodore A. Omachi, Sam Khalil, James L. Zazzali   +9 more
openalex   +1 more source

Wells syndrome: clinical findings and management in a large cohort of 48 patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives: Wells syndrome (WS) is a rare inflammatory skin disorder typically characterized by erythematous, edematous, and pruritic plaques. Despite its distinct histopathological features, WS remains an underdiagnosed disease due to its variable clinical presentations and overlap with other dermatological conditions.
Marco Adriano Chessa, Silvia Robuffo, Tullio Brunetti, Luca Rapparini, Bianca Maria Piraccini, Cosimo Misciali, Beatrice Raone, Iria Neri, Federica Filippi   +8 more
wiley   +1 more source

Unveiling Rare Genetic Variants in DAB2IP: New Insights Into the Pathogenesis of Recurrent Angioedema

Allergy, EarlyView.
Maurizio Margaglione, Maria D'Apolito, Rosa Santacroce, Giorgia Cordisco, Francesco Arcoleo, Tiziana De Pasquale, Ilaria Puxeddu, Andrea Zanichelli, Mauro Cancian   +8 more
wiley   +1 more source

Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review

International Journal of Dermatology, EarlyView.
ABSTRACT Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment.
Yagiz Matthew Akiska, Isha Gandhi, Robert Adler, Deena Fayyad, Perya Bhagchandani, Shabnam Afzal, Waleed Adawi, Shivani Patel, Shawn G. Kwatra   +8 more
wiley   +1 more source